Advantage Alpha Capital Partners LP Grows Stake in TG Therapeutics, Inc. $TGTX

Advantage Alpha Capital Partners LP raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 53.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,588 shares of the biopharmaceutical company’s stock after acquiring an additional 7,141 shares during the period. Advantage Alpha Capital Partners LP’s holdings in TG Therapeutics were worth $812,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the business. CWM LLC boosted its position in shares of TG Therapeutics by 16.2% during the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 290 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company’s stock valued at $34,000 after acquiring an additional 433 shares during the period. Xponance Inc. lifted its holdings in TG Therapeutics by 5.3% in the first quarter. Xponance Inc. now owns 10,861 shares of the biopharmaceutical company’s stock valued at $428,000 after acquiring an additional 543 shares during the period. Choreo LLC lifted its holdings in TG Therapeutics by 7.6% in the first quarter. Choreo LLC now owns 8,547 shares of the biopharmaceutical company’s stock valued at $337,000 after acquiring an additional 602 shares during the period. Finally, NBC Securities Inc. lifted its holdings in TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 823 shares during the period. 58.58% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, The Goldman Sachs Group raised TG Therapeutics to a “hold” rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.25.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the firm’s stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director owned 228,816 shares of the company’s stock, valued at $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.64% of the stock is owned by company insiders.

TG Therapeutics Stock Up 1.6%

NASDAQ TGTX opened at $28.77 on Friday. The stock’s 50-day moving average price is $34.23 and its 200-day moving average price is $35.71. The company has a quick ratio of 2.96, a current ratio of 3.86 and a debt-to-equity ratio of 0.89. TG Therapeutics, Inc. has a 52 week low of $21.11 and a 52 week high of $46.48. The company has a market capitalization of $4.56 billion, a P/E ratio of 77.76 and a beta of 1.95.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.32 by ($0.15). TG Therapeutics had a return on equity of 26.05% and a net margin of 13.31%.The company had revenue of $141.15 million during the quarter, compared to the consensus estimate of $147.76 million. During the same period last year, the business earned $0.04 EPS. The firm’s quarterly revenue was up 92.1% compared to the same quarter last year. TG Therapeutics has set its FY 2025 guidance at EPS. On average, equities research analysts predict that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.